Dublin, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The "Gene Editing Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.
This report contains a comprehensive listing of 384 gene editing deals announced since 2016 including financial terms where available including links to online deal records of actual gene editing partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Gene Editing Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene editing deals entered into by the world's leading biopharma companies. Fully revised and updated, the report provides details of gene editing deals from 2016 to 2025.
The report provides a detailed understanding and analysis of how and why companies enter gene editing deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research and licensing deals.
The initial chapters offer an overview of gene editing dealmaking. It begins with an introduction, followed by trends observed since 2016. It then details the leading gene editing deals according to headline value and provides a listing of the top 25 most active companies in gene editing dealmaking. This is complemented by a comprehensive review of deals, focusing on available contract documents and specific gene editing technologies. Chapters provide both overview and detailed insight into the sector's partnering landscape.
The report also includes numerous tables and figures that illustrate the trends and activities in gene editing dealmaking since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z, deal type, and therapeutic target. Each deal title links via Weblink to an online version of the deal record and, where available, the contract document, providing easy access to each contract document on demand.
Gene Editing Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2016
- Browse gene editing collaboration and licensing deals
- Benchmark analysis - identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, deal type and therapy area
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in gene editing dealmaking
2.1. Introduction
2.2. Gene editing deals over the years
2.3. Most active gene editing dealmakers
2.4. Gene editing deals by deal type
2.5. Gene editing deals by therapy area
2.6. Gene editing deals by industry sector
2.7. Deal terms for gene editing deals
2.7.1 Gene editing deals headline values
2.7.2 Gene editing deal upfront payments
2.7.3 Gene editing deal milestone payments
2.7.4 Gene editing royalty rates
Chapter 3 - Leading gene editing deals
3.1. Introduction
3.2. Top gene editing deals by value
Chapter 4 - Most active gene editing dealmakers
4.1. Introduction
4.2. Most active gene editing dealmakers
4.3. Most active gene editing deals company profiles
Chapter 5 - Gene editing contracts dealmaking directory
5.1. Introduction
5.2. Gene editing contracts dealmaking directory
Chapter 6 - Gene editing dealmaking by technology type
Deal directory
Deal directory - Gene editing deals by company A-Z
Deal directory - Gene editing deals by deal type
Deal directory - Gene editing deals by therapy area
Deal type definitions
Companies Featured
- Abbvie
- Amazon Web Services
- AstraZeneca
- Bayer
- Biogen
- Bluebird Bio
- Boehringer Ingelheim
- Bristol-Myers Squibb
- CRISPR Therapeutics
- Charles River Laboratories
- Columbia University
- Duke University
- Eli Lilly
- Emory University
- Francis Crick Institute
- Genentech
- Gilead Sciences
- GlaxoSmithKline (GSK)
- Harvard University
- Illumina
- Janssen Pharmaceuticals
- Johns Hopkins University
- Massachusetts Institute of Technology
- Merck and Co
- Moderna
- National Institutes of Health
- Novartis
- Pfizer
- Regeneron Pharmaceuticals
- Roche
- Sana Biotechnology
- Sangamo Therapeutics
- Sarepta Therapeutics
- Stanford University
- Takeda Pharmaceutical
- Thermo Fisher Scientific
- University of California, Berkeley
- University of California, Los Angeles
- University of California, San Francisco
- University of Cambridge
- University of Oxford
- University of Pennsylvania
- University of Washington
- Vanderbilt University
- Vertex Pharmaceuticals
- Yale University
- Abbott Laboratories
- CVS Health
- Tesla
- SpaceX
For more information about this report visit https://www.researchandmarkets.com/r/wf1jbc
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
